{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:45:10Z","timestamp":1787589910041,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shanghai LianBio Development Co., Ltd."},{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jacasi.2025.05.015","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T14:10:15Z","timestamp":1751983815000},"page":"1064-1074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects of Mavacamten on Cardiac Magnetic Resonance Features in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"5","author":[{"given":"Zhuang","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoquan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian\u2019an","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jacasi.2025.05.015_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"issue":"21","key":"10.1016\/j.jacasi.2025.05.015_bib2","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"issue":"37","key":"10.1016\/j.jacasi.2025.05.015_bib3","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jacasi.2025.05.015_bib4","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.3390\/jcm12103481","article-title":"Cardiac magnetic resonance in HCM phenocopies: from diagnosis to risk stratification and therapeutic management","volume":"12","author":"Licordari","year":"2023","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.jacasi.2025.05.015_bib5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jcmg.2012.06.003","article-title":"LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice","volume":"5","author":"Armstrong","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.jacasi.2025.05.015_bib6","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1038\/s41598-017-06533-0","article-title":"Incremental benefit of late gadolinium cardiac magnetic resonance imaging for risk stratification in patients with hypertrophic cardiomyopathy","volume":"7","author":"Doesch","year":"2017","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.jacasi.2025.05.015_bib7","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jcmg.2016.02.031","article-title":"Prognostic value of LGE-CMR in HCM: a meta-analysis","volume":"9","author":"Weng","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"issue":"10253","key":"10.1016\/j.jacasi.2025.05.015_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jacasi.2025.05.015_bib9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2025.05.015_bib10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0735-1097(23)00770-2","article-title":"96-week cardiac magnetic resonance results of treatment with mavacamten from the EXPLORER cohort of the MAVA-long-term extension study in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Saberi","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacasi.2025.05.015_bib11","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.jacasi.2025.05.015_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-071473","article-title":"Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy","volume":"13","author":"Tian","year":"2023","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.jacasi.2025.05.015_bib13","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s10554-021-02165-8","article-title":"Prognostic significance of cardiac magnetic resonance-based markers in patients with hypertrophic cardiomyopathy","volume":"37","author":"Dohy","year":"2021","journal-title":"Int J Cardiovasc Imaging"},{"issue":"7","key":"10.1016\/j.jacasi.2025.05.015_bib14","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2004.06.024","article-title":"Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy","volume":"94","author":"Losi","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacasi.2025.05.015_bib15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1476-7120-9-34","article-title":"Left atrial volume predicts adverse cardiac and cerebrovascular events in patients with hypertrophic cardiomyopathy","volume":"9","author":"Tani","year":"2011","journal-title":"Cardiovasc Ultrasound"},{"issue":"19","key":"10.1016\/j.jacasi.2025.05.015_bib16","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.jacc.2024.08.015","article-title":"Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy","volume":"84","author":"Masri","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jacasi.2025.05.015_bib17","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s10554-015-0720-0","article-title":"Systolic and diastolic myocardial mechanics in hypertrophic cardiomyopathy and their link to the extent of hypertrophy, replacement fibrosis and interstitial fibrosis","volume":"31","author":"Nucifora","year":"2015","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jacasi.2025.05.015_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.amjcard.2020.04.042","article-title":"Prediction and prevention of sudden death in young patients (<20 years) with hypertrophic cardiomyopathy","volume":"128","author":"Rowin","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacasi.2025.05.015_bib19","article-title":"Model embraced electromechanical coupling time for estimation of heart failure in patients with hypertrophic cardiomyopathy","volume":"9","author":"Hu","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"10.1016\/j.jacasi.2025.05.015_bib20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2010.11.013","article-title":"Assessment of myocardial fibrosis with cardiovascular magnetic resonance","volume":"57","author":"Mewton","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacasi.2025.05.015_bib21","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2010.05.007","article-title":"Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy","volume":"56","author":"Bruder","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacasi.2025.05.015_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.109.854026","article-title":"Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy","volume":"3","author":"Rubinshtein","year":"2010","journal-title":"Circ Heart Fail"},{"issue":"11","key":"10.1016\/j.jacasi.2025.05.015_bib23","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jacc.2010.05.010","article-title":"Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy","volume":"56","author":"O'Hanlon","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacasi.2025.05.015_bib24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.jacasi.2025.05.015_bib25","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/01.CIR.0000095029.57483.60","article-title":"Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy","volume":"108","author":"Bello","year":"2003","journal-title":"Circulation"},{"issue":"6273","key":"10.1016\/j.jacasi.2025.05.015_bib26","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"issue":"30","key":"10.1016\/j.jacasi.2025.05.015_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo7622","article-title":"Mavacamten, a precision medicine for hypertrophic cardiomyopathy: From a motor protein to patients","volume":"9","author":"Nag","year":"2023","journal-title":"Sci Adv"},{"issue":"2","key":"10.1016\/j.jacasi.2025.05.015_bib28","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0008-6363(97)00258-7","article-title":"Modulation of contractility in human cardiac hypertrophy by myosin essential light chain isoforms","volume":"37","author":"Schaub","year":"1998","journal-title":"Cardiovasc Res"},{"issue":"6","key":"10.1016\/j.jacasi.2025.05.015_bib29","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.cardfail.2019.03.016","article-title":"Myocardial contraction fraction predicts cardiovascular events in patients with hypertrophic cardiomyopathy and normal ejection fraction","volume":"25","author":"Shimada","year":"2019","journal-title":"J Card Fail"},{"issue":"8","key":"10.1016\/j.jacasi.2025.05.015_bib30","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacasi.2025.05.015_bib31","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"5","key":"10.1016\/j.jacasi.2025.05.015_bib32","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/echo.13158","article-title":"Impact of septal reduction on left atrial size and diastole in hypertrophic cardiomyopathy","volume":"33","author":"Finocchiaro","year":"2016","journal-title":"Echocardiography"},{"issue":"2","key":"10.1016\/j.jacasi.2025.05.015_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5603\/KP.a2018.0242","article-title":"Reduction of left ventricular mass, left atrial size, and N-terminal pro-B-type natriuretic peptide level following alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy","volume":"77","author":"Dabrowski","year":"2019","journal-title":"Kardiol Pol"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374725002881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374725002881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:31:57Z","timestamp":1762644717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772374725002881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2772374725002881"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2025.05.015","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Mavacamten on Cardiac Magnetic Resonance Features in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2025.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}